MedTrace Logo

Efficacy and Safety of Inetetamab Combined With Pyrotinib and Vinorelbine in ABC

NCT05856383 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2023-05-12

No results posted yet for this study

Summary

This is a prospective, no interventional, single arm cohort study, which aims to study the efficacy and safety of inetetamab combined with pyrotinib and vinorelbine in the Treatment of HER2 positive advanced breast cancer in the real world. The study will be conducted by signing an informed consent form for study enrollment, collecting patient case information, and conducting observation and follow-up.

Conditions

  • HER2-positive Advanced Breast Cancer

Interventions

DRUG

Inetetamab Combined With Pyrotinib and Vinorelbine

Inetetamab Combined With Pyrotinib and Vinorelbine

Sponsors & Collaborators

  • Zhejiang Cancer Hospital

    lead OTHER

Principal Investigators

  • Chen zhanhong · Zhejiang Cancer Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-16
Primary Completion
2027-12-31
Completion
2027-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05856383 on ClinicalTrials.gov